Result of Placing and EGM

The MedicX Fund Limited
29 May 2007


For Immediate Release                                               29 May 2007



   NOT FOR DISTRIBUTION, PUBLICATION OR RELEASE IN OR INTO THE UNITED STATES,
         CANADA, AUSTRALIA, JAPAN, NEW ZEALAND, IRELAND OR SOUTH AFRICA


                                 ADVERTISEMENT


This document does not constitute or form part of any offer or invitation to
sell or issue, or any solicitation of any offer to subscribe for, any C Shares
or any other securities, nor shall it (or any part of it), or the fact of its
distribution, form the basis of, or be relied on in connection with, any
contract relating thereto. This document is an advertisement and not a
prospectus, and investors should not subscribe for any C Shares referred to in
this document except on the basis of the information in the Prospectus. Copies
of the Prospectus are available from the Company's registered office.


Prospective investors should only rely on the information contained in the
Prospectus. No person has been authorised to give any information or make any
representation other than those contained in the Prospectus. If given or made,
such information must not be relied upon as having been authorised by the
Company or Panmure Gordon (UK) Limited ('Panmure Gordon').


                              MedicX Fund Limited

                  ('MedicX Fund', 'the Fund' or 'the Company')


  Result of Placing and Offer for Subscription for C Shares and EGM held today


Further to the announcement on 2 May 2007 of a proposed Placing and Offer to
subscribe for C Shares in MedicX Fund Limited (MXF), the Official Listed
specialist investor in modern purpose built primary healthcare properties, the
Directors of the Company today announce that the Company has successfully raised
£22.2 million (before expenses), by way of a Placing and Offer for Subscription
of C Shares at 100p per share. The proceeds from the Issue will be used to fund
the Company's investment programme in primary healthcare properties.


At the Extraordinary General Meeting held today, the special resolution
approving the Issue was passed by the Company's shareholders. The Placing and
Offer for Subscription remain conditional upon Admission to the Official List of
the London Stock Exchange, which is expected to take place at 8.00am on 4 June
2007 with dealings in the C Shares expected to commence shortly thereafter. The
ticker symbol for the C Shares will be MXFC. Panmure Gordon is acting as sponsor
and broker in respect of the Placing and Offer for Subscription.


All terms used in this announcement are defined as set out in the Prospectus
dated 2 May 2007.


                                    - ends -

For further information please contact:

MedicX Fund
Alison Simpson                                               Tel: [phone]

MedicX Group
Keith Maddin                                                 Tel: [phone]

Mike Adams

Buchanan Communications
Charles Ryland                                               Tel: [phone]

Lisa Baderoon

Mary-Jane Johnson

Panmure Gordon (UK) Limited
Edward Farmer                                                Tel: [phone]

Stuart Gledhill

Callum Stewart


The contents of this announcement have been approved for the purposes of section
21 of the Financial Services and Markets Act 2000 as amended ('FSMA') by Panmure
Gordon (UK) Limited ('Panmure Gordon') of Moorgate Hall, 155 Moorgate, London,
EC2M 6XB. Panmure Gordon is authorised and regulated in the United Kingdom by
the Financial Services Authority in respect of regulated activities and is
acting as sponsor and broker in respect of the Placing and Offer for
Subscription. Panmure Gordon is acting solely for MedicX Fund Limited in
connection with the Placing and Offer for Subscription and will not be
responsible to anyone other than MedicX Fund Limited for providing the
protections afforded to clients of Panmure Gordon nor for providing advice in
relation to the Placing and Offer for Subscription.


This announcement is not for release, publication or distribution, in whole or
in part, in or into the United States, Australia, Canada, Japan, South Africa,
New Zealand, the Republic of Ireland or Australia (the 'Prohibited Territories
'). The Shares have not been and will not be registered under the US Securities
Act of 1933 (as amended), the United States Investment Company Act of 1940 (as
amended) or under the applicable securities laws of the other Prohibited
Territories and, unless an exemption under such laws is available, may not be
offered for sale or subscription or sold or subscribed directly or indirectly
within the USA or the other Prohibited Territories or for the account or benefit
of any national, resident or citizen of the USA or the other Prohibited
Territories.


Copies of the Prospectus are available during normal business hours on any
weekday (Saturdays, Sundays and public holidays excepted) at the offices of
Panmure Gordon, Moorgate Hall, 155 Moorgate, London EC2M 6XB until Admission and
for the 14 days following Admission. The Prospectus is also available at the
document viewing facility of the UKLA at the UKLA Document Viewing Facility,
Financial Services Authority, 25 The North Colonnade, Canary Wharf, London E14
5HS.



                      This information is provided by RNS
            The company news service from the London Stock Exchange